Common Names: European chestnut
Chestnut shell extract has potential health benefits. It showed neuroprotective, hypoglycemic, and hypolipidemic properties by inhibiting certain enzymes. Phenolic compounds in the extract can be absorbed by the intestines and reach target sites.
Scientists studied the ink disease that causes decline in chestnut orchards. They used RNA interference to suppress a gene in the pathogen, allowing them to assess the effects on the host plant. This research could lead to better understanding and management of the disease.
This study examines the impact of digestion on the bioactivity of chestnut shell extract. Results show reduced phenolic concentrations but retained antioxidant, hypoglycemic, and neuroprotective properties. Digestion leads to the biotransformation of phenolic compounds. This highlights the potential value of chestnut shell extract as a nutraceutical ingredient.
This study identified and quantified various phenolic compounds in chestnuts, including dicarboxylic acid derivatives, hydroxybenzoic acids, hydroxycinnamic acids, and flavanols. Contrary to the assumption, commercial hybrid cultivars did not have a superior metabolic profile compared to "native" accessions.
Chestnut leaf extracts have been found to have a higher anti-neuroinflammatory effect than spiny bur extracts in a study using BV-2 microglial cells as a model of neuroinflammation. The study also discovered specific flavonoids and unsaturated fatty acids in the leaf extract that are responsible for the observed effects. This research demonstrates the potential of chestnut by-products as a source of bioactive compounds and provides opportunities for the valorization of waste material generated during chestnut processing while satisfying consumer demand for natural compounds.